摘要
乳腺癌为女性最常见的癌症,对于激素受体(hormone receptor,HR)阳性的乳腺癌患者,新辅助内分泌治疗(neoadjuvant endocrine therapy,NET)是一种有效的治疗策略。本文围绕NET与新辅助化疗(neoadjuvant chemotherapy,NCT)疗效对比、NET联合化疗或靶向治疗、NET的预测指标等方面进行综述。
Breast cancer is the most common cancer in women,and neoadjuvant endocrine therapy(NET)is an effective treatment strategy for hormone receptor(HR)-positive breast cancer.This review focuses on the efficacy of NET compared with neoadjuvant chemotherapy(NCT),NET combined with chemotherapy or targeted therapy,and the predictors of NET.
作者
莫一敏
吴骁凡
俞星飞
杨红健
Mo Yimin;Wu Xiaofan;Yu Xingfei;Yang Hongjian(The 2nd Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou 310053,China;Department of Breast Surgery,Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou 310022,China)
出处
《中华内分泌外科杂志（中英文）》
CAS
2024年第2期313-316,共4页
Chinese Journal of Endocrine Surgery
基金
浙江省卫生健康科技计划(2022KY670)。
关键词
乳腺癌
激素受体阳性
新辅助治疗
Breast cancer
Hormone receptor positive
Neoadjuvant therapy
